To fill this gap, we integrated the PANoScore with multiple clinical factors, including tumor grade, IDH status, 1p19q status, and the MGMT promoter status, and developed a PANoptosis-related risk score (PANo-RRS) via multivariate Cox analysis in the TCGA-Glioma cohort. This evidence concerns the gene MGMT and glioma.